

<b>Allegato A</b>			
<b>NOME COMPOSTO</b>	<b>SINTESI DELLE INDICAZIONI GIÀ AUTORIZZATE</b> <i>Indicazioni secondo la legge 648/96</i>	<b>ESTENSIONE DELLE INDICAZIONI SULLA BASE DI NUOVE EVIDENZE SCIENTIFICHE</b>	<b>BIBLIOGRAFIA</b> <b>A SOSTEGNO DELL'ESTENSIONE DELL'INDICAZIONE</b>
<b>ACICLOVIR</b>	- <b>Infezioni da Herpes simplex</b>  - <b>Infezioni da Herpes zoster</b>	-Sindrome da fatica cronica	Lopez-Navidad A et al. Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. Scand J Infect Dis 1996; 28:185-187  Drago F et al. Epstein-Barr-virus-related primary cutaneous amyloidosis. Successful treatment with acyclovir and interferon-alpha. Br J Dermatol 1996; 134:170-174
<b>ACIDO NERIDRONICO</b>	- <b>Osteogenesi imperfetta</b>  - <b>Morbo di Paget</b>	-Osteoporosi  -Osteoporosi: pazienti con esofagite-ulcera gastroduodenale  -Osteoporosi: resistenza ad altri bisfosfonati	Braga V et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003;33:342-345  Cascella T et al. Effects of neridronate treatment in elderly women with osteoporosis. J Endocrinol Invest 2005;28:202-208  Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39-47
<b>ACIDO PAMIDRONICO</b>	- <b>Metastasi ossee prevalentemente litiche</b>  - <b>Mieloma multiplo</b>  - <b>Ipercalcemia provocata da osteolisi neoplastica</b>	-Spondilite anchilosante: resistenza o controindicazione ad altra terapia con farmaci biologici         -Spondiloartriti resistenti a FANS e/o non candidate a	Lavie F et al. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:346-352  Toussirot E and Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:340-345  Grover R et al. Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 2006;65:688-689  Maksymowych WP et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.

		terapia con farmaci biologici	<p>Arthritis Rheum 2002;46:766-773</p> <p>Toussirot E and Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother 2005;6:35-43</p> <p>Maksymowych WP et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144-155</p>
<b>ADALIMUMAB</b>	<p><b>-Artrite reumatoide</b></p> <p><b>-Artrite psoriasica</b></p> <p><b>-Spondilite anchilosante</b></p> <p><b>-Spondiloartriti</b></p> <p><b>-Psoriasi</b></p> <p><b>-Malattia di Crohn</b></p> <p><i>-Trattamento di pazienti con uveite grave refrattaria correlata ad artrite idiopatica giovanile, intolleranti o refrattari a infliximab</i></p>	<p>-Pioderma gangrenoso</p> <p>-Arterite di Horton</p> <p>-Malattia di Behçet</p> <p>-Sarcoidosi</p> <p>-Arterite di Takayasu</p>	<p>Fonder MA et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006;5:e8</p> <p>Heffernan MP et al. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol 2007;143:306-308</p> <p>Pomerantz RG et al. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007;157:1274-1285</p> <p>Ahmed MM et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353-1355</p> <p>Mushtaq B et al. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 2007;21:824-825</p> <p>Van Laar JAM et al. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007;66:565-566</p> <p>Callejas-Rubio JL et al. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006;25:596-597</p> <p>Denys BG et al. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Cli Sci 2007;112:281-289</p> <p>Heffernan MP and Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006;142:17-19</p> <p>Tato F et al. Refractory Takayasu's arteritis successfully treated with the human,</p>

		<p>-Eritema nodoso</p> <p>-Granulomatosi di Wegener</p> <p>-Malattie infiammatorie intestinali</p> <p>-Malattie infiammatorie intestinali nel bambino</p> <p>-Malattie infiammatorie intestinali in gravidanza e concepimento</p>	<p>monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005;24:304-307</p> <p>Ortego-Centeno N et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007;21:408-410</p> <p>Mukhtyar C and Luqmani R. Current state of tumor necrosis factor [alpha] blockade in Wegener's granulomatosis. Ann Rheum Dis 2005;64:31-36</p> <p>Kozuch PL and Hanawer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354-377</p> <p>Behm BW and Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893</p> <p>Noe JD and Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008. Epub ahead of print</p> <p>Shepela C. The safety of biologic agents in the treatment of inflammatory bowel disease. Minn Med 2008;91:42-45</p> <p>Coburn LA et al. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006;51:2045-2047</p> <p>O'Donnell S and O'Morain C. Review article: use of antitumor necrosis factor therapy in inflammatory disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27:885-894</p>
<b>AMITRIPTILINA</b>	<p><b>-Depressione endogena</b></p> <p><b>-Fase depressiva della psicosi maniaco-depressiva</b></p> <p><b>-Profilassi dell'emicrania e delle cefalee croniche o ricorrenti</b></p>	-Fibromialgia	<p>Uçeyler N et al. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59:1279-1298</p> <p>Ozerbil O et al. Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol 2006;25:495-497</p> <p>Goldenberg D et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-1859</p>

<b>AMLODIPINA</b>	<b>-Ipertensione arteriosa</b> <b>-Angina pectoris</b>	-Fenomeno di Raynaud idiopatico e secondario	Sturgill MG and Seibold JR. Rational use of calcium-channel antagonists in Raynaud's phenomenon. <i>Curr Opin Rheumatol</i> 1998;10:584-588
<b>ANAKINRA</b>	<b>-Artrite reumatoide</b>	-Morbo di Still dell'adulto  -Sindromi auto-infiammatorie  -Spondilite anchilosante  -Sindrome di Schnitzler	Fitzgerald AA et al. Rapid response to anakinra in patients with refractory adult-onset Still's disease. <i>Arthritis Rheum</i> 2005;52:1794-1803  Vasques Godinho FM et al. Refractory adult onset Still's disease successfully treated with anakinra. <i>Ann Rheum Dis</i> 2005;64:647-648  Kalliolias GD and Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. <i>Expert Opin Investig Drugs</i> 2008;17:349-359  Hawkins PN et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. <i>Arthritis Rheum</i> 2004;50:607-612  Simon A et al. Beneficial response to interleukin 1 receptor antagonist in traps. <i>Am J Med</i> 2004;117:208-210  Dierselhuis MP et al. Anakinra for flares of pyogenic arthritis in PAPA syndrome. <i>Rheumatology</i> 2005;44:406-408  Haibel H et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. <i>Ann Rheum Dis</i> 2005;64:296-268  Tan AL et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. <i>Ann Rheum Dis</i> 2004;63:1041-1045  Bennett AN et al. Sustained response to anakinra in ankylosing spondylitis. <i>Rheumatology</i> 2008;47:223-224  Schneider SW et al. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. <i>J Am Acad Dermatol</i> 2007;56:120-122  Gilson M et al. Treatment of Schnitzler's syndrome with anakinra. <i>Clin Exp Rheumatol</i> 2007;25:931



	<p><b>autoimmune</b></p> <p><b>-Porpora trombocitopenica idiopatica</b></p>	<p>nell'impegno polmonare</p> <p>-Malattia di Behçet</p> <p>-Crioglobulinemia mista</p> <p>-Vasculiti cutanee</p> <p>-Arterite di Horton</p>	<p>azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis Rheum</i> 2006;54:3962-3970</p> <p>Hamuryudan V et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. <i>Arthritis Rheum</i> 1997;40:769-774</p> <p>Yazici H et al. A controlled trial of azathioprine in Behçet's syndrome. <i>N Engl J Med</i> 1990;322:281-285</p> <p>Gul A. Standard and novel therapeutic approaches to Behçet disease. <i>Drugs</i> 2007;67:2013-2022</p> <p>Garini G et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. <i>Ann Ital Med Int</i> 2005;20:71-80</p> <p>Gross WL. New concepts in treatment protocols for severe systemic vasculitis. <i>Curr Opin Rheumatol</i> 1999;11:41-46</p> <p>Chen KR and Carlson JA. Clinical approach to cutaneous vasculitis. <i>Am J Clin Dermatol</i> 2008;9:71-92</p> <p>Rogalski C and Sticherling M. Panarteritis cutanea benigna--an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. <i>Int J Dermatol</i> 2007;46:817-821</p> <p>Pipitone N and Salvarani C. Improving therapeutic options for patients with giant cell arteritis. <i>Curr Opin Rheumatol</i> 2008;20:17-22</p> <p>Salvarani C et al. Diagnosis and management of polymyalgia rheumatica/giant cell arteritis. <i>BioDrugs</i> 1998;9:25-32</p>
<p><b>CICLOFOSFAMIDE</b></p>	<p><b>-Trattamento citostatico</b></p>	<p>-Vasculiti ANCA correlate: terapia di induzione</p>	<p>de Groot K et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheum</i> 2005;52:2461-2469</p> <p>Bosch X et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a</p>

			<p>systematic review. JAMA 2007;298:655-669</p> <p>Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int 2007;56:87-96</p>
		-Miositi: impegno polmonare	<p>Kameda H et al. Combination therapy with corticosteroids, cyclosporin A and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-1726</p> <p>Bombardieri S et al. Cyclophosphamide in severe polymyositis. Lancet 1989;1:1138-1139</p> <p>Yamasaki Y et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007;46:124-130</p>
		-Lupus: nefrite	<p>Boumpas DT et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745</p> <p>Mok CC et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:25-33</p> <p>Seong SS et al. Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatol Int 2008;28:453-458</p>
		-Lupus: attività di malattia	<p>Neuwelt CM et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41</p> <p>Barile-Fabris L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;64:620-625</p> <p>Medeiros MM et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med 2008;19:122-128</p>
		-Sclerodermia: interstiziopatia	<p>Antoniou SA. Cyclophosphamide for scleroderma interstitial lung disease. Expert Opin Investig Drugs 2007;16:393-395</p>

		<p>polmonare</p> <p>-Granulomatosi di Wegener</p> <p>-Crioglobulinemia mista: gravi manifestazioni vasculitiche (glomerulonefrite, vasculite addominale, neuropatia sensitivo-motoria)</p> <p>-Malattia di Behçet</p>	<p>Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. <i>N Engl J Med</i> 2006;354:2655-2666</p> <p>Khanna D et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis Rheum</i> 2007;56:1676-1684</p> <p>Langford CA et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. <i>Am J Med</i> 2003;114:463-469</p> <p>Marder W and McCune WJ. Advances in immunosuppressive therapy. <i>Semin Respir Crit Care Med</i> 2007;28:398-417</p> <p>Pagnoux C and Teixeira L. Wegener's granulomatosis. <i>Presse Med</i> 2007;36:860-874</p> <p>Garini G et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. <i>Ann Ital Med Int</i> 2005;20:71-80</p> <p>Kayali Z et al. Treatment of hepatitis C cryoglobulinemia: mission and challenges. <i>Curr Treat Opin Gastroenterol</i> 2006;9:497-507</p> <p>Souayah N et al. Hepatitis C virus acute quadriparetic vasculitic neuropathy responsive to cyclophosphamide. <i>Neurol Neurophysiol Neurosci</i> 2006;18:5</p> <p>Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. <i>Surv Ophthalmol</i> 2005;50:297-350</p> <p>Du LT et al. Value of "bolus" cyclophosphamide injections in Behçet's disease. Experience of 17 cases. <i>Presse Med</i> 1990;19:1355-1358</p> <p>Melillo N et al. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease. <i>Clin Rheumatol</i> 2007;26:1365-1367</p>
--	--	---	---



<b>CICLOSPORINA</b>	<ul style="list-style-type: none"> <li>-<b>Trapianti</b></li> <li>-<b>Artrite reumatoide</b></li> <li>-<b>Uveite endogena</b></li> <li>-<b>Sindrome nefrosica</b></li> <li>-<b>Psoriasi</b></li> <li>-<b>Dermatite atopica</b></li>   <li>-<i>Malattie autoimmuni gravi</i></li> </ul>	<ul style="list-style-type: none"> <li>- Orticaria cronica autoimmune idiopatica: steroido-risparmiatore, forme refrattarie</li>   <li>-Artrite psoriasica</li>   <li>-Lupus: impegno cutaneo</li>   <li>-Malattie autoimmuni: HCV correlate</li> </ul>	<p>Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004;114:465-474</p> <p>Fradin MS et al. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991;25:1065-1067</p> <p>Gordon KB et al. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Derm 2006;54:85-91</p> <p>Fraser AD. A randomised, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporine in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-864</p> <p>Sarzi Puttini P et al. Long term safety and efficacy of low dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002;21:234-238</p> <p>Callen JP. Management of “refractory” skin disease in patients with lupus eritematosus. Best Pract Res Clin Rheumatol 2005;19:767-784</p> <p>Wozniacka A et al. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. Clin Rheumatol 2007;26:1176-1179</p> <p>Hilgard P et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol 2006;12:697-702</p> <p>Goto K et al. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporine A and NIM811. Biochem Biophys Res Commun 2006;343:879-884</p>
<b>CLONAZEPAM</b>	<ul style="list-style-type: none"> <li>-<b>Epilessia</b></li> </ul>	<ul style="list-style-type: none"> <li>-Fenomeno di Raynaud</li> </ul>	<p>Colakoglu M et al. Effect of clonazepam on Raynaud’s phenomenon and fingertip ulcers in scleroderma. Ann Pharmacother 2007;41:1544-1547</p>
<b>CLOROCHINA</b>	<ul style="list-style-type: none"> <li>-<b>Profilassi e trattamento della malaria</b></li> <li>-<b>Amebiasi extraintestinale</b></li> </ul>	<ul style="list-style-type: none"> <li>-Sindrome di Sjogren: manifestazioni ghiandolari ed extraghiandolari</li> </ul>	<p>Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract Res Clin Rheumatol 2006;20:791-807</p> <p>Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-329</p>

	<p><b>-Artrite reumatoide (poliartrite cronica), comprese le forme giovanili</b></p> <p><b>- Lupus eritematoso discoide cronico</b></p> <p><b>-Lupus eritematoso sistemico</b></p>	<p>-Dermatomiosite: manifestazioni cutanee</p> <p>- Sindrome da anticorpi antifosfolipidi</p> <p>-Lupus: terapia di mantenimento</p> <p>-Lupus in corso di gravidanza</p>	<p>Ang GC and Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005;141:855-859</p> <p>Wallace DJ. The use of chloroquine and hydroxychloroquine for non infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5:59-64</p> <p>Roubey RA. Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 2002;14:238-242</p> <p>Suarez IM et al. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus 1996;5:81-83</p> <p>Sisó A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281-288</p> <p>Tam LS et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000;27:2142-2145</p>
<p><b>COLCHICINA</b></p>	<p><b>-Gotta</b></p>	<p>-Aftosi</p> <p>-Vasculiti cutanee</p>	<p>Altenburg A et al. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007;21:1019-1026</p> <p>Fontes V et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol 2002;129:1365-1369</p> <p>Katz J et al. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol 1994;31:459-461</p> <p>Carlson JA et al. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006;24:414-429</p> <p>Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1985;13:193-200</p> <p>Hazen PG and Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behçet's syndrome. Arch Dermatol 1979;115:1303-1306</p>

		<p>-Febbre mediterranea familiare</p> <p>-Artriti microcristalline</p>	<p>Tufan A et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. <i>J Rheumatol</i> 2007;34:1540-1544</p> <p>Cerquaglia C et al. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. <i>Curr Drug Targets Inflamm Allergy</i> 2005;4:117-124</p> <p>Kosan C and Ozkan B. Once-daily use of colchicine in children with familial Mediterranean fever. <i>Clin Pediatr</i> 2004;43:605-608</p> <p>Announ N and Guerne PA. Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy. <i>Z Rheumatol</i> 2007;66:573-578</p> <p>Lioté F and Ea HK. Recent developments in crystal-induced inflammation pathogenesis and management. <i>Curr Rheumatol Rep</i> 2007;9:343-350</p> <p>Rosenthal AK and Ryan LM. Treatment of refractory crystal-associated arthritis. <i>Rheum Dis Clin North Am</i> 1995;21:151-161</p>
<b>COTRIMOSSA-ZOLO</b>	<b>- Infezioni delle vie respiratorie, renali, delle vie urinarie, dell'apparato genitale e dell'apparato digerente</b>	-Granulomatosi di Wegener	<p>Ohtake T et al. Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. <i>Intern Med</i> 2001;40:666-670</p> <p>Stegeman CA et al. Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-trimoxazole Wegener Study Group. <i>N Eng J Med</i> 1996;335:16-20</p> <p>Reinhold-Keller E et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. <i>QJM</i> 1996;89:15-23</p>
<b>DOXICICLINA</b>	<b>- Infezioni da germi sensibili alle tetracicline</b>	-Artrite reumatoide	<p>O'Dell JR et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. <i>Arthritis Rheum</i> 2006;54:621-627</p> <p>Gompels LL et al. Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis. <i>J Rheumatol</i> 2006;33:224-227</p> <p>Alarcon GS. Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy. <i>Nat Clin Pract Rheumatol</i> 2006;2:296-</p>

		-Malattie infiammatorie croniche	297  Webster G and Del Rosso JQ. Anti-inflammatory activity of tetracyclines. <i>Dermatol Clin</i> 2007;25:133-135  Voils SA et al. Use of macrolides and tetracyclines for chronic inflammatory diseases. <i>Ann Pharmacother</i> 2005;39:86-94  Sapadin AN and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. <i>J Am Acad Dermatol</i> 2006;54:258-265
<b>DULOXETINA</b>	- <b>Depressione maggiore</b>  - <b>Dolore neuropatico diabetico periferico</b>	-Fibromialgia	Arnold LM et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. <i>Arthritis Rheum</i> 2004;50:2974-2984  Arnold LM et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. <i>J Womens Health</i> 2007;16:1145-1156  Russell IJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. <i>Pain</i> 2008;136:232-234
<b>ETANERCEPT</b>	- <b>Artrite reumatoide</b>  - <b>Psoriasi</b>  - <b>Spondilite anchilosante</b>	-Vasculiti ANCA-correlate          -Amiloidosi	Sinico RA and Sabadini E. New insights in the treatment of ANCA-associated systemic vasculitis. <i>G Ital Nefrol</i> 2006;23:138-148  Little MA et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. <i>J Am Soc Nephrol</i> 2006;17:160-169  Huugen D et al. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. <i>Clin J Am Soc Nephrol</i> 2006;1:1100-1107  Drewe E and Powell RJ. Etanercept AL amyloidosis. <i>Lancet</i> 2001;358:761  Gottenberg JE et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of

			<p>tolerability and efficacy. <i>Arthritis Rheum</i> 2003;48:2019-2024</p> <p>Perry ME et al. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. <i>Clin Rheumatol</i> 2008;27:923-925</p>
		-Malattia di Behçet	<p>Atzeni F et al. Successful treatment of resistant Behçet's disease with etanercept. <i>Clin Exp Rheumatol</i> 2005;23:729</p> <p>Melikoglu M et al. Short-term of etanercept in Behçet's disease: a double blind, placebo controlled study. <i>J Rheumatol</i> 2005;32:98-105</p> <p>Sfikakis PP et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. <i>Rheumatology</i> 2007;46:736-741</p>
		-Arterite di Horton	<p>Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. <i>J Rheumatol</i> 2004;31:1467</p> <p>Tan AL et al. Successful treatment of resistant giant cell arteritis with etanercept. <i>Ann Rheum Dis</i> 2003;62:373-374</p> <p>Martínez-Taboada VM et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. <i>Ann Rheum Dis</i> 2008;67:625-630</p>
		-Morbo di Still dell'adulto	<p>Husni ME et al. Etanercept in the treatment of adult patients with Still's disease. <i>Arthritis Rheum</i> 2002;46:1171-1176</p> <p>Fautrel B et al. Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. <i>Ann Rheum Dis</i> 2005;64:262-266</p>
		-Dermatomiositi	<p>Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. <i>Ann Rheum Dis</i> 2006;65:1233-1236</p> <p>Iannone F et al. Use of etanercept in the treatment of dermatomyositis: a case series. <i>J Rheumatol</i> 2005;33:1802-1804</p>

		-Polimiositi	<p>Sprott H et al. Treatment of myositis with etanercept (Enbrel), a recombinant human fusion protein of TNF-alpha type II receptor and IgG1. <i>Rheumatology</i> 2004;43:524-526</p> <p>Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. <i>Ann Rheum Dis</i> 2006;65:1233-1236</p> <p>Wendling D et al. Anti TNF-alpha treatment of a refractory polymyositis. <i>Rev Med Interne</i> 2007;28:194-195</p>
		-Sindrome SAPHO	<p>Wagner AD et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. <i>Arthritis Rheum</i> 2002;46:1965-1968</p>
		-Sclerosi sistemica	<p>Bosello S et al. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. <i>Ann Intern Med</i> 2005;143:918-920</p> <p>Lam GK et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. <i>J Rheumatol</i> 2007;34:1636-1637</p>
		-Sarcoidosi	<p>Khanna D et al. Etanercept ameliorates sarcoidosis arthritis and skin disease. <i>J Rheumatol</i> 2003;30:1864-1867</p> <p>Utz JP et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. <i>Chest</i> 2003;124:177-185</p> <p>Tuchinda C and Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. <i>J Drugs Dermatol</i> 2006;5:538-540</p>
<b>FELODIPINA</b>	<p><b>-Ipertensione arteriosa</b></p> <p><b>-Angina pectoris</b></p>	-Fenomeno di Raynaud idiopatico e secondario	<p>Sturgill MG and Seibold JR. Rational use of calcium-channel antagonists in Raynaud's phenomenon. <i>Curr Opin Rheumatol</i> 1998;10:584-588</p> <p>Kallenberg CG et al. Once daily felodipine in patients with primary Raynaud's phenomenon. <i>Eur J Clin Pharmacol</i> 1991;40:313-315</p>

<b>FLUOXETINA</b>	<ul style="list-style-type: none"> <li>- <b>Depressione maggiore</b></li> <li>- <b>Disturbo ossessivo compulsivo</b></li> <li>- <b>Bulimia nervosa</b></li> </ul>	-Fibromialgia	<p>Ozerbil O et al. Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol 2006;25:495-497</p> <p>Goldenberg D et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-1859</p>
<b>GABAPENTIN</b>	<ul style="list-style-type: none"> <li>- <b>Epilessia</b></li> <li>- <b>Dolore neuropatico periferico</b></li> <li>- <b>Disturbo d'ansia generalizzato</b></li> </ul>	-Fibromialgia	<p>Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008;20:246-250</p> <p>Arnold LM et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-1344</p>
<b>IDROSSI-CLOROCHINA</b>	<ul style="list-style-type: none"> <li>- <b>Artrite reumatoide</b></li> <li>- <b>Lupus eritematoso (discoide o sistemico)</b></li> </ul>	<ul style="list-style-type: none"> <li>- <b>Sindrome di Sjogren: manifestazioni ghiandolari ed extraghiandolari</b></li> <li>- <b>Dermatomiosite: manifestazioni cutanee</b></li> <li>- <b>Osteoartrosi erosiva</b></li> <li>- <b>Sindrome da anticorpi</b></li> </ul>	<p>Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract Res Clin Rheumatol 2006;20:791-807</p> <p>Dawson LJ et al. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology 2005;44:449-455</p> <p>Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-329</p> <p>Ang GC and Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005;141:855-859</p> <p>Wallace DJ. The use of chloroquine and hydroxychloroquine for non infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5:59-64</p> <p>Vuolteenaho K et al. Aureothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. Scand J Rheumatol 2005;34:475-479</p> <p>Bryant LR et al. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 1995;8:1527-1531</p> <p>Yoon KH. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid syndrome. J Rheumatol 2002;29:1574-1575</p>

		antifosfolipidi	<p>Espinola RG et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. <i>Thromb Haemost</i> 2002;3:518-522</p> <p>Roubey RA. Treatment of the antiphospholipid syndrome. <i>Curr Opin Rheumatol</i> 2002;14:238-242</p>
		-Lupus: terapia di mantenimento	<p>Tsakonas E et al. A long term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. <i>Lupus</i> 1998;7:80-85</p> <p>Sisó A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. <i>Lupus</i> 2008;17:281-288</p> <p>Ruiz-Irastorza G and Khamashta M. Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> 2008;17:271-273</p>
		-Lupus in corso di gravidanza	<p>Levy RA. Hydroxychloroquine (HCQ) in lupus pregnancy: double blind and placebo controlled study. <i>Lupus</i> 2001;10:401-404</p> <p>Costedoat-Chalumeau N et al. Safety of hydroxychloroquine in pregnant patients with connective tissues diseases: a study of one hundred thirty-three cases compared with a control group. <i>Arthritis Rheum</i> 2003;48:3207-3211</p> <p>Tam LS et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. <i>J Rheumatol</i> 2000;27:2142-2145</p>
		-Artriti croniche in gravidanza	<p>Tandon VR et al. Pregnancy and rheumatoid arthritis. <i>Indian Med Sci</i> 2006;60:334-344</p> <p>Ostensen M and Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? <i>Drug Saf</i> 1998;19:389-410</p> <p>Vroom F et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. <i>Drug Saf</i> 2006;29:845-863</p>
<b>ILOPROST</b>	<b>-Tromboangioite obliterante (morbo di Bürger) in stadio</b>	-Ipertensione polmonare	<p>Hachulla E et al. Iloprost for the treatment of systemic sclerosis. <i>Presse Med</i> 2008;37:831-839</p>



	<p><b>avanzato</b></p> <p><b>-Ischemia arteriosa cronica grave degli arti inferiori</b></p> <p><b>-Fenomeno di Raynaud secondario a sclerodermia</b></p>		<p>Launay D et al. Pulmonary arterial hypertension and systemic sclerosis. <i>Presse Med</i> 2006;35:1929-1937</p> <p>Caramaschi P et al. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. <i>Rheumatol Int</i> 2006;27:203-205</p>
<b>IMMUNO-GLOBULINE</b>	<p><b>-Terapia sostitutiva</b></p> <p><b>-Porpora trombocitopenica idiopatica</b></p> <p><b>-Sindrome di Guillain Barré</b></p> <p><b>-Poliradicolo-neuropatia cronica</b></p> <p><b>-Neuropatia motoria multifocale</b></p> <p><b>-Sindrome di Kawasaki</b></p> <p><b>-Trapianto allogenico di midollo osseo</b></p> <p><b>-Infezioni</b></p> <p><b>-Malattia da trapianto verso l'ospite</b></p>	<p>-Miositi</p> <p>-Dermatomiosite (lesioni cutanee)</p> <p>-Miosite in corso di gravidanza</p> <p>-Artrite reumatoide</p> <p>-Lupus eritematoso sistemico</p>	<p>Dalakas MC. The role of high-dose immunoglobulins intravenous in the treatment of dermatomyositis. <i>Int Immunopharmacol</i> 2006;6:550-556</p> <p>Al-Mayouf SM et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. <i>J Rheumatol</i> 2000;27:2498-2503</p> <p>Kuwano Y et al. Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. <i>Acta Derm Venereol</i> 2006;86:158-159</p> <p>Sadayama T et al. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesion. <i>J Dermatol</i> 1999;26:457-459</p> <p>Williams L et al. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. <i>Obstet Gynecol</i> 2007;109:561-563</p> <p>Muscat C et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. <i>Ann Rheum Dis</i> 1995;54:382-385</p> <p>Pap T et al. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. <i>Scand J Rheumatol</i> 1998;27:157-159</p> <p>Maeda H et al. Successful treatment of 'malignant rheumatoid arthritis' in Japan with pooled intravenous immunoglobulin. <i>Rheumatology</i> 2001;40:955-956</p> <p>Sherer Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. <i>Autoimmun Rev</i> 2006;5:153-155</p> <p>Zandman-Goddard G et al. Intravenous immunoglobulin therapy and systemic lupus erythematosus. <i>Clin Rev Allergy Immunol</i> 2005;29:219-228</p>

		<p>-Lupus: impegno neuropsichiatrico</p> <p>-Lupus: impegno renale</p> <p>-Lupus in corso di gravidanza</p> <p>-Sindrome da anticorpi antifosfolipidi (anche in corso di gravidanza)</p>	<p>Sherer Y et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. <i>Isr Med Assoc J</i> 2008;10:55-57</p> <p>Milstone AM et al. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. <i>Clin Rheumatol</i> 2005;24:394-397</p> <p>Lazurova I et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. <i>Clin Rheumatol</i> 2007;26:2145-2147</p> <p>Rauova L et al. High-dose intravenous immunoglobulins for lupus nephritis – a salvage immunomodulation. <i>Lupus</i> 2001;10:209-213</p> <p>Boletis JN et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. <i>Lancet</i> 1999;354:569-570</p> <p>Monova D et al. Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. <i>Nephron</i> 2002;90:262-266</p> <p>Gordon C and Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. <i>Lupus</i> 1998;7:429-433</p> <p>Perricone R et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. <i>Rheumatology</i> 2008;47:646-651</p> <p>Gordon C and Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. <i>Lupus</i> 1998;7:429-433</p> <p>Triolo G et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. <i>Arthritis Rheum</i> 2003;48:728-731</p> <p>Konova E. Intravenous immunoglobulin therapy in antiphospholipid syndrome. <i>Clin</i></p>
--	--	--	---

		<p>- Ictus da sindrome da anticorpi antifosfolipidi</p> <p>- Altre patologie autoimmuni</p> <p>-Sclerosi sistemica</p>	<p>Rev Allergy Immunol 2005;29:229-236 Hsiao GR et al. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 2001;7:336-339</p> <p>Horn HC et al. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus 2004;13:478-480</p> <p>De Vita S et al. High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 1996;14:85-92</p> <p>Shoenfeld Y et al. IV Ig therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005;38:123-137</p> <p>Miniati I et al. Pregnancy in systemic sclerosis. Rheumatology 2008;47:16-18</p> <p>Nacci F et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-979</p> <p>Levy Y et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin. A preliminary report. Clin Rheumatol 2000;19:207-211</p>
<b>INFLIXIMAB</b>	<p><b>-Artrite reumatoide</b></p> <p><b>-Artrite psoriasica</b></p> <p><b>-Spondilite anchilosante</b></p> <p><b>-Colite ulcerosa</b></p> <p><b>-Malattia di Crohn</b></p> <p><b>-Psoriasi</b></p> <p><i>-Trattamento di pazienti con uveite severa refrattaria correlata ad artrite idiopatica giovanile</i></p>	<p>-Vasculiti ANCA correlate</p> <p>-Arterite di Takayasu</p>	<p>Sinico RA and Sabadini E. New insights in the treatment of ANCA-associated systemic vasculitis. G Ital Nefrol 2006;23:138-148</p> <p>Little MA et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006;17:160-169</p> <p>Huugen D et al. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol 2006;1:1100-1107</p> <p>Hoffman GS et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-2304</p> <p>Karageorgaki ZT et al. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 2007;26:984-987</p>

			<p>Tanaka F et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006;45:313-316</p>
		-Malattia di Behçet: impegno oculare	<p>Niccoli L et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-1164</p> <p>Abu El-Asrar AM et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophtalmol 2005;26:83-92</p> <p>Lanthier N et al. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005;34:916-918</p>
		-Malattia di Behçet: impegno neurologico	<p>Ribi C et al. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-1735</p> <p>Sarwar H et al. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005;32:181-183</p> <p>López Rodríguez M et al. Biological therapy with anti-TNF antibodies. Extending the spectrum of its indications? Rev Clin Esp 2007;207:448-450</p>
		-Malattia di Behçet: afte, lesioni mucocutanee	<p>Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs 2007;67:2013-2022</p> <p>Sfikakis PP et al. Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology 2007;46:736-741</p> <p>Takamoto M et al. Long-term infliximab treatment for Behçet's disease. Jpn J Ophthalmol 2007;51:239-240</p>
		-Malattia di Behçet: impegno intestinale	<p>Lee JH et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-27</p>
		-Arterite di Horton: impegno oculare grave e/o refrattario	<p>Torrente SV et al. Amaurosis in patients with giant cell arthritis: treatment with anti-tumor necrosis factor alpha. Intern Med J 2007;37:1280-1291</p> <p>Uthman I et al. Infliximab as a monotherapy in giant cell arteritis. Clin Rheumatol</p>

			2006;25:109-110
		-Pioderma gangrenoso: lesioni gravi associate a patologie autoimmuni	<p>Bacon PA. Should infliximab be used to help maintain glucocorticosteroid-induced remission in patients with giant cell arteritis? <i>Nat Clin Pract Rheumatol</i> 2007;3:600-601</p> <p>Brooklyn TN et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized double blind, placebo controlled trial. <i>Gut</i> 2006;55:505-509</p> <p>Reguirai Z and Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease. <i>Am J Clin Dermatol</i> 2007;8:66-67</p> <p>Reichrath J et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. <i>J Am Acad Dermatol</i> 2005;53:273-283</p>
		- Morbo di Still dell'adulto	<p>Kraetsch HG et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. <i>Ann Rheum Dis</i> 2001;60:55-57</p> <p>Fautrel B et al. Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. <i>Ann Rheum Dis</i> 2005;64:262-266</p> <p>Cavagna L et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. <i>Clin Exp Rheumatol</i> 2001;19:329-332</p>
		-Amiloidosi	<p>Elkayam O et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. <i>Arthritis Rheum</i> 2002;46:571-573</p> <p>Gottemberg JE et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritis: a follow-up report of tolerability and efficacy. <i>Arthritis Rheum</i> 2003;48:2019-2024</p> <p>Ortiz-Santamaria V et al. Treatment of secondary amyloidosis with infliximab. <i>Rheumatology</i> 2003;42:1425-1426</p>
		-Dermatomiosite	Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of

		<p>-Polimiosite</p> <p>-Sindrome SAPHO</p> <p>-Sclerosi sistemica</p>	<p>resistant dermatomyositis and polymyositis: a retrospective study of eight patients. <i>Ann Rheum Dis</i> 2006;65:1233-1236</p> <p>Korkmaz C et al. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumor necrosis factor-alpha. <i>Rheumatology</i> 2004;43:937-938</p> <p>Hengstman GJ et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. <i>Eur Neurol</i> 2008;59:159-163</p> <p>Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. <i>Ann Rheum Dis</i> 2006;65:1233-1236</p> <p>Wendling D et al. Anti TNF-alpha treatment of a refractory polymyositis. <i>Rev Med Interne</i> 2007;28:194-195</p> <p>Wagner AD et al. Sustained response to tumor necrosis factor alpha-bloking agents in two patients with SAPHO syndrome. <i>Arthritis Rheum</i> 2002;46:1965-1968</p> <p>Olivieri I et al. Pharmacological management of SAPHO syndrome. <i>Expert Opin Investig Drugs</i> 2006;15:1229-1233</p> <p>Bosello S et al. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. <i>Ann Intern Med</i> 2005;143:918-920</p> <p>Antoniou KM et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. <i>Clin Exp Rheumatol</i> 2007;25:23-28</p>
<b>ISRADIPINA</b>	<p><b>-Ipertensione arteriosa</b></p> <p><b>-Angina pectoris</b></p>	<p>-Fenomeno di Raynaud idiopatico e secondario</p>	<p>Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's phenomenon. <i>Curr Opin Rheumatol</i> 1998;10:584-588</p> <p>La Civita L et al. Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon. <i>Ann Rheum Dis</i> 1996;55:331-332</p> <p>Leppert J et al. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. <i>Cardiovasc</i></p>

			Drugs Ther 1989;3:397-401
<b>LEFLUNOMIDE</b>	<ul style="list-style-type: none"> <li>-Artrite reumatoide</li> <li>-Artrite psoriasica attiva</li> </ul>	<ul style="list-style-type: none"> <li>-Sclerodermia: artrite</li> <li>-Granulomatosi di Wegener: mantenimento</li> <li>-Dermatomiosite</li> </ul>	<p>Sebastiani M et al. Successful treatment with leflunomide of arthritis in systemic sclerosis patients. <i>Rheumatology</i> 2006;45:1175-1176</p> <p>Metzler C et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. <i>Rheumatology</i> 2004;43:315-332</p> <p>Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. <i>Rheumatology</i> 2007;46:1047-1048</p> <p>Boswell JS and Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. <i>J Am Acad Dermatol</i> 2008;58:403-406</p>
<b>METOTREXATO</b>	<ul style="list-style-type: none"> <li>-Tumori</li> <li>-Artrite reumatoide</li> <li>-Artrite psoriasica</li> </ul>	<ul style="list-style-type: none"> <li>-Vasculiti ANCA correlate: terapia di mantenimento nelle manifestazioni di malattia senza pericolo di vita</li> <li>-Vasculiti ANCA correlate: glomerulonefrite</li> <li>-Miositi: steroido-risparmiatore</li> </ul>	<p>Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. <i>Curr Opin Rheumatol</i> 2007;19:17-24</p> <p>Bosch X et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. <i>JAMA</i> 2007;298:655-669</p> <p>Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. <i>Allergol Int</i> 2007;56:87-96</p> <p>Little MA and Pusey CD. Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. <i>Nephrology</i> 2005;10:368-376</p> <p>Bohan A et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. <i>Medicine</i> 1977;56:255-286</p> <p>Vencovsky J et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. <i>Scand J Rheumatol</i> 2000;29:95-102</p> <p>Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. <i>Neuromuscul Disord</i> 2006; 16: 223-226</p>

		<p>-Spondiloartriti: interessamento periferico</p> <p>-Sclerodermia</p> <p>-Lupus eritematoso sistemico</p> <p>-Lupus: impegno cutaneo</p> <p>-Polimialgia reumatica: steroideo - risparmiatore</p>	<p>Toussirot E et al. Late-onset ankylosing spondylitis and related spondyloarthropathies: clinical and radiological characteristics and pharmacological treatment options. <i>Drugs Aging</i> 2005;22:451-469</p> <p>Kataria RK and Brent LH. Spondyloarthropathies. <i>Am Fam Physician</i> 2004; 69:2853-2860</p> <p>Queiro R De Dios Jr. Successful treatment with low-dose weekly methotrexate in a case of undifferentiated spondyloarthropathy coexisting with cutaneous polyarteritis nodosa. <i>Clin Rheumatol</i> 2002;21:304-305</p> <p>Krishna Sumanth M et al. Evaluation of oral methotrexate in the treatment of systemic sclerosis. <i>Int J Dermatol</i> 2007;46:218-223</p> <p>Van den Hoogen FH et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. <i>Br J Rheumatol</i> 1996;35:364-372</p> <p>Blank N et al. The role of DMARDs in systemic sclerosis therapy. <i>Rheumatology</i> 2006;45:42-44</p> <p>Wong JM and Esdaile JM. Methotrexate in systemic lupus erythematosus. <i>Lupus</i> 2005;14:101-105</p> <p>Sanchez Y and Carvallo A. Methotrexate use in patients with systemic lupus erythematosus. <i>Rev Med Chil</i> 2004;132:195-201</p> <p>Sato EI. Methotrexate therapy in systemic lupus erythematosus. <i>Lupus</i> 2001;10:162-164</p> <p>Kuhn A et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>J Am Acad Dermatol</i> 2002;46:600-603</p> <p>Soubrier M et al. Polymyalgia rheumatica: diagnosis and treatment. <i>Joint Bone Spine</i> 2006;73:599-605</p> <p>Pipitone N et al. Are steroids alone sufficient for the treatment of giant cell arteritis? <i>Best Pract Res Clin Rheumatol</i> 2005;19:277-292</p>
--	--	---	--



			<p>Caporali R et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med</i> 2004;141:493-500</p>
		-Malattia di Behçet	<p>Lin P and Liang G. Behçet disease: recommendation for clinical management of mucocutaneous lesions. <i>J Clin Rheumatol</i> 2006;12:282-286</p> <p>Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. <i>Surv Ophthalmol</i> 2005;50:297-350</p> <p>Davatchi F et al. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. <i>Adv Exp Med Biol</i> 2003;528:579-584</p>
		- Malattia di Behçet: manifestazioni neurologiche	<p>Kikuchi H et al. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. <i>Adv Exp Med Biol</i> 2003;528:575-578</p> <p>Hirohata S et al. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. <i>J Neurol Sci</i> 1998;159:181-185</p> <p>Kaklamani VG and Kaklamanis PG. Treatment of Behçet's disease-an update. <i>Semin Arthritis Rheum</i> 2001;30:299-312</p>
		-Arterite di Horton	<p>Pipitone N and Salvarani C. Improving therapeutic options for patients with giant cell arteritis. <i>Curr Opin Rheumatol</i> 2008;20:17-22</p> <p>Rimar D et al. Giant cell arteritis: the methotrexate debate revisited. <i>J Rheumatol</i> 2006;33:1458-1459</p> <p>Mahr AD et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. <i>Arthritis Rheum</i> 2007;56:2789-2797</p>
		-Fascite eosinofila	<p>Pouplin S et al. Treatment of eosinophilic fascitis with methotrexate. <i>J Rheumatol</i> 1998;25:606-607</p> <p>Janzen L et al. Response to methotrexate in a patient with idiopathic eosinophilic fascitis, morphea, IgM hypergammaglobulinemia, and renal involvement. <i>J Rheumatol</i> 1995;22:1967-1970</p>

		<p>-Granulomatosi di Wegener</p> <p>-Vasculiti cutanee</p>	<p>Bischoff L and Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008;47:29-35</p> <p>Shimizu T et al. A case of refractory Wegener's granulomatosis successfully treated with high-dose methotrexate. Nihon Kokyuki Gakkai Zasshi 2006;44:853-857</p> <p>Specks U. Methotrexate for Wegener's granulomatosis: what is the evidence? Arthritis Rheum 2005;52:2237-2242</p> <p>Langford CA et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469</p> <p>Carlson JA et al. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006;24:414-429</p>
<b>MICOFENOLATO MOFETILE</b>	<p><b>-Rigetto acuto</b></p> <p><i>-Malattia del "trapianto verso ospite", nella forma sia acuta che cronica, resistente o intollerante al trapianto di 1° e 2° linea, dopo trapianto allogenico di cellule staminali emopoietiche</i></p> <p><i>-Malattie autoimmuni gravi</i></p>	<p>-Artrite reumatoide refrattaria ad altre terapie</p> <p>-Artrite psoriasica</p> <p>-Orticaria cronica idiopatica refrattaria ad altre terapie</p> <p>-Malattie autoimmuni refrattarie ad altre terapie</p> <p>-Malattie autoimmuni HCV-correlate</p>	<p>Drosos AA. Newer immunosuppressives drugs: their potential role in rheumatoid arthritis therapy. Drugs 2002;62:891-907</p> <p>Grundmann-Kollman M et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000;42: 835-837</p> <p>Shahar E et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients non responding to antihistamines and/or corticosteroids. Int J Dermatol 2006;45:1224-1227</p> <p>Iaccarino L et al. Mycophenolate mofetil: what in its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190-195</p> <p>Henry SD et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon alpha. Gastroenterology 2006;131:1452-1460</p>

		-Vasculiti cutanee	Russell JP and Weenig RH. Primary cutaneous small vessel vasculitis. <i>Curr Treat Options Cardiovasc Med</i> 2004;6:139-149
<b>MICOFENOLATO SODICO</b>	<b>-Rigetto acuto</b>	-Lupus: glomerulonefrite  -Sindrome di Sjogren  -Intolleranza gastrica al micofenolato mofetile	Mak SK et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. <i>Nephrology</i> 2008;13:331-336  Kitiyacara C et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. <i>Clin Nephrol</i> 2008; 69:90-101  Willeke P et al. Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. <i>Arthritis Res Ther</i> 2007;9:R115  Sanchez Fructuoso A et al. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. <i>Transplant Proc</i> 2007;39:2194-2196  Bolin P et al. Improvement in 3 month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric coated mycophenolate sodium in renal transplant patients. <i>Transplantation</i> 2007; 84:1443-1451  Chan L et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric coated mycophenolate sodium. <i>Transplantation</i> 2007;81:1290-1297
<b>NICARDIPINA</b>	<b>-Ipertensione arteriosa</b> <b>-Angina pectoris</b>	-Fenomeno di Raynaud idiopatico e secondario	Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's phenomenon. <i>Curr Opin Rheumatol</i> 1998;10:584-588  No authors listed. Controlled multicenter double-blind trial of nifedipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France. <i>Am Heart J</i> 1991;122:352-355
<b>NIFEDIPINA</b>	<b>-Ipertensione arteriosa</b> <b>-Angina pectoris</b>	-Fenomeno di Raynaud idiopatico e secondario	Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's phenomenon. <i>Curr Opin Rheumatol</i> 1998;10:584-588  Belch JJ and Ho M. Pharmacotherapy of Raynaud's phenomenon. <i>Drugs</i> 1996;52:682-695  Maricq HR et al. Evaluation of treatment efficacy of Raynaud's phenomenon by digital blood response to cooling. <i>Vasc Med</i> 2000;5:135-140

<b>NISOLDIPINA</b>	<ul style="list-style-type: none"> <li>-Ipertensione arteriosa</li> <li>-Angina pectoris</li> </ul>	-Fenomeno di Raynaud idiopatico e secondario	Gjørup T et al. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986;31:387-389
<b>PAROXETINA</b>	<ul style="list-style-type: none"> <li>-Depressione maggiore</li> <li>-Disturbo ossessivo compulsivo</li> <li>-Disturbo da attacchi di panico con o senza agorafobia</li> <li>- Disturbo d'ansia sociale/fobia sociale</li> <li>-Disturbo d'ansia generalizzata</li> <li>-Disturbo da stress post-traumatico</li> </ul>	-Fibromialgia	Patkar AA et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120:448-454
<b>PIMECROLIMUS</b>	-Dermatite atopica	-Lupus: impegno cutaneo	<p>Luger T and Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215:45-54</p> <p>Tzellos TG and Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008;64:337-341</p> <p>Wollina U and Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1-6</p>
<b>PRAVASTATINA</b>	<ul style="list-style-type: none"> <li>-Ipercolesterolemia</li> <li>-Ipertrigliceridemia</li> <li>-Iperlipidemie</li> </ul>	<ul style="list-style-type: none"> <li>-Sclerosi sistemica</li> <li>-Lupus eritematoso</li> </ul>	<p>Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-339</p> <p>Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 2006;18:594-600</p> <p>Furukawa S et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006;65:1118-1120</p> <p>Costenbader KH. A pravastatin dose-escalation study in systemic lupus erythematosus</p>

		sistemico	Rheumatol Int 2007;27:1071-1077  Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005;19:823-838
<b>PREGABALIN</b>	-Epilessia  -Dolore neuropatico periferico e centrale  -Disturbo d'ansia generalizzato	-Fibromialgia	Mease PJ et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514  Owen RT. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 2007;43:857-863  Arnold LM et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007; 8:633-638
<b>RITUXIMAB</b>	-Linfomi  -Artrite reumatoide  <i>-Linfoma non-Hodgkin follicolare, di immunofenotipo CD20</i>  <i>-Tutti i linfomi non Hodgkin di Burkitt o tipo Burkitt immunofenotipo CD 20 positivo</i>	-Vasculiti ANCA correlate  -Granulomatosi di Wegener    -Piastrinopenia autoimmune: forme refrattarie ad altre terapie    -Crioglobulinemia	Keogh KA et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-268  Hinze CH and Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 2008;34:372-379  Aouba A et al. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008;34:65-73  Keogh KA et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187  George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-1672  Niewold TB et al. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 2006;33:1194-1196  Braendstrup P et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-280  Roccatello D et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.

		mista	<p>Clin Rev Allergy Immunol 2008;34:111-117</p> <p>Bryce AH et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 2006;7:140-144</p> <p>Zaja F et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-3834</p>
		-Crioglobulinemia mista: impegno renale	<p>Kamar N et al. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-439</p> <p>Bruchfeld A et al. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia-anti-viral therapy vs rituximab. Rheumatology 2006;45:783-784</p> <p>Quartuccio L et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842-846</p>
		-Crioglobulinemia mista: impegno epatico	<p>Saadoun D et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23-28</p> <p>Dore MP et al. Cryoglobulinemia related to hepatitis C virus infection. Dig Dis Sci 2007;52:897-907</p> <p>Pekow J and Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006;40:450</p>
		-Crioglobulinemia mista: impegno nevritico	<p>Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 2005;112:115-125</p> <p>Cai FZ et al. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006;33:1197-1198</p>
		-Crioglobulinemia mista: impegno cutaneo	<p>Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J 2006;12:3</p> <p>Ramos-Casals M and Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005;17:447-455</p>

		<p>-Altre malattie autoimmuni</p>	<p>Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol 2006;77:24-28</p>
		<p>-Dermatomiosite e polimiosite: forme refrattarie</p>	<p>Gottenberg JE et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-920</p> <p>Galarza C et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allerg Immunol 2008;34: 124-128</p>
		<p>-Dermatomiosite e polimiosite: forme refrattarie</p>	<p>Liossis SN and Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008;127:280-285</p> <p>Noss EH et al. Rituximab as a therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-1026</p> <p>Lamotte O et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-1370</p>
		<p>-Dermatomiosite e polimiosite: sindrome antisintetasi</p>	<p>Brulhart L et al. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-975</p>
		<p>-Dermatomiosite e polimiosite: manifestazioni cardiache</p>	<p>Touma Z et al. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334-337</p>
		<p>-Dermatomiosite e polimiosite: manifestazioni cutanee</p>	<p>Dinh HV et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148-153</p>
		<p>-Lupus eritematoso sistemico</p>	<p>Thatayatikom A and White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006;5:18-24</p>

			<p>Lindholm C et al. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. <i>J Rheumatol</i> 2008;35:826-833</p> <p>Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). <i>Endocr Metab Immune Disord Drug Targets</i> 2006;6:345-350</p> <p>Looney RJ et al. New therapies for systemic lupus erythematosus: cellular targets. <i>Rheum Dis Clin North Am</i> 2006;32:201-215</p> <p>Mikiko T et al. Efficacy of rituximab for refractory systemic lupus erythematosus involving the central nervous system. <i>Ann Rheum Dis</i> 2007;66:470-475</p> <p>Armstrong DJ et al. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). <i>Rheumatol Int</i> 2006;26: 771-772</p>
		-Lupus: impegno neurologico	
		-Neuropatie autoimmuni	<p>Rojas-Garcia R et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. <i>Neurology</i> 2003;61:1814-1816</p>
		-Sindrome da anticorpi antifosfolipidi	<p>Anandacoomarasamy A et al. 'Cure' of life threatening antiphospholipid syndrome with rituximab. <i>Intern Med J</i> 2006;36:474-475</p> <p>Rubenstein E et al. Rituximab treatment for resistant antiphospholipid syndrome. <i>J Rheumatol</i> 2006;33:355-357</p> <p>Merrill JT. Rituximab in antiphospholipid syndrome. <i>Curr Rheumatol Rep</i> 2003;5:381-382</p>
		-Anemia emolitica refrattaria	<p>D'Arena G et al. Monoclonal antibodies: new therapeutic agents for autoimmune haemolytic anemia? <i>Endocr Metab Immune Disord Drug Targets</i> 2008;8:62-68</p> <p>Martinez-Velasco E et al. The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia. <i>Farm Hosp</i> 2007;31:124-127</p> <p>Wang L et al. Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anemia. <i>Zhongguo Shi Yan Ye Xue Za Zhi</i> 2007;15:425-428</p>



<b>SERTRALINA</b>	<b>-Depressione</b> <b>-Depressione associata ad ansia</b> <b>-Disturbo ossessivo-compulsivo</b> <b>-Disturbo da attacchi di panico con o senza agorafobia</b>	-Fibromialgia: astenia	Gonzalez-Viejo MA et al. A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment. <i>Ann Readapt Med Phys</i> 2005;48:610-615  Ozgoemen S et al. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. <i>Rheumatol Int</i> 2006;26:598-603
<b>SILDENAFIL</b>	<b>-Disfunzione erettile</b>	-Sclerodermia: ulcere  -Fenomeno di Raynaud: ulcere  -Sclerodermia: ipertensione polmonare  -Connettiviti: ipertensione polmonare	Chung L Fiorentino D. Digital ulcers in patients with systemic sclerosis. <i>Autoimmun Rev</i> 2006;5:125-128  Gore J and Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. <i>Ann Rheum Dis</i> 2005;64:1387  Colglazier CL et al. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. <i>J Rheumatol</i> 2005;32:2440-2442  Pope JE. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. <i>Drugs</i> 2007;67:517-525  Jiménez López-Guarch C et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results. <i>Rev Esp Cardiol</i> 2004;57:946-951  Ruiz MJ et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. <i>J Heart Lung Transplant</i> 2006;25:1353-1357  Singh TP et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. <i>Am Heart J</i> 2006;151:1-5  Badesch DB et al. Sildenafil for pulmonary hypertension associated with connective tissue disease. <i>J Rheumatol</i> 2007;34:2417-2422

<b>SIMVASTATINA</b>	<b>-Iperolesterolemia</b> <b>-Ipertrigliceridemia</b> <b>-Iperlipidemie</b>	Sclerosi sistemica	<p>Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. <i>Curr Opin Rheumatol</i> 2006;18:594-600</p> <p>Del Papa N et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. <i>J Rheumatol</i> 2008;35:1323-1328</p>
<b>SULFASALAZINA</b>	<b>-Colite ulcerosa</b> <b>-Malattia di Crohn</b> <b>-Artrite reumatoide</b>	<b>-Artrite psoriasica</b>  <b>-Spondilite anchilosante</b>  <b>- Artrite cronica in gravidanza</b>	<p>Marguerie L et al. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. <i>Join Bone Spine</i> 2002;69:275-281</p> <p>Soriano ER and McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. <i>J Rheumatol</i> 2006;33:1422-1430</p> <p>Akkoc N et al. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. <i>Best Pract Res Clin Rheumatol</i> 2006;20:539-557</p> <p>Chen J and Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. <i>J Rheumatol</i> 2006;33:722-731</p> <p>Vroom F et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implication for the future. <i>Drug Saf</i> 2006;29:845-863</p> <p>Ostensen M and Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? <i>Drug Saf</i> 1998;19:389-410</p> <p>Ostensen M. Optimization of antirheumatic drug treatment in pregnancy <i>Clin Pharmacokinet</i> 1994;27:486-503</p>
<b>TACROLIMUS</b>	<b>Uso sistemico:</b> <b>-Profilassi del rigetto del trapianto allogenico di rene o di fegato</b> <b>- Trattamento del rigetto allogenico resistente al trattamento con altri immunosoppressori</b> <b>Uso topico:</b>	<b>-Sclerodermia</b>          <b>-Lupus: impegno</b>	<p>Lafyatis R. Targeting fibrosis in systemic sclerosis. <i>Endocr Metab Immune Disord Drug Targets</i> 2006;6:395-400</p> <p>Asano Y et al. Differential effects of the immunosuppressant FK-506 on human alpha2 (I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. <i>Arthritis Rheum</i> 2005;52:1237-1247</p> <p>Morton SJ and Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. <i>Rheumatology</i> 2000;39:865-869</p> <p>Tzellos TG and Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of</p>

	<b>-Dermatite atopica</b>	cutaneo	<p>cutaneous lupus erythematosus: an evidence based evaluation. Eur J Clin Pharmacol 2008;64:337-341</p> <p>Wollina U and Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1-6</p> <p>Sugano M et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006;33:887-891</p>
		-Dermatomiosite: impegno cutaneo	<p>Peyrot I et al. Topical tacrolimus and resistant skin lesions of dermatomyositis. Rev Med Interne 2006;27:730-735</p> <p>Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006;8:167-173</p> <p>Holar CB et al. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004;15:35-39</p>
		-Orticaria	<p>Kessel A et al. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005;52:145-148</p>
		-Malattia di Behçet	<p>Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297-350</p> <p>Sakane T et al. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi 1995;35:802-813</p> <p>Koga T et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. Chest 1993;104:309-311</p>
<b>UROCHINASI</b>	<b>-Occlusioni venose o arteriose acute di origine trombotica o embolica</b>	-Sclerodermia: impegno cutaneo	<p>Margheri F et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional beta 2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006;54:3926-3938</p> <p>D'Alessio S et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004;50:3275-3285</p>

			Bazzichi L et al. Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination. Scand J Rheumatol 2003;32:264-267
<b>VALGANCICLOVIR</b>	<b>-Infezioni da Herpes simplex</b> <b>-Infezioni da Herpes zoster</b>	-Sindrome da fatica cronica	Lopez-Navidad A et al. Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. Scand J Infect Dis 1996;28:185-187  Kogelnik AM et al. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006;37:33-38